{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:20:12Z","timestamp":1777350012161,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:00:00Z","timestamp":1539648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","award":["15\/194\/10"],"award-info":[{"award-number":["15\/194\/10"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40273-018-0718-2","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T12:18:18Z","timestamp":1539692298000},"page":"345-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"37","author":[{"given":"Tosin","family":"Lambe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-7415","authenticated-orcid":false,"given":"Rui","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Nevitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janette","family":"Greenhalgh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Boland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Beale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor","family":"Kotas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"McEntee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Pomeroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,16]]},"reference":[{"key":"718_CR1","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. 2013. http:\/\/www.nice.org.uk\/article\/pmg9\/resources\/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf . Accessed 1 Jun 2015."},{"key":"718_CR2","unstructured":"National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 . Accessed Aug 2017."},{"key":"718_CR3","unstructured":"National Institute for Health and Care Excellence (NICE). Cladribine tablets for treating relapsing-remitting multiple sclerosis [TA493].\u00a0 https:\/\/www.nice.org.uk\/guidance\/ta493 . Accessed 6 Dec 2017."},{"issue":"9648","key":"718_CR4","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502\u201317.","journal-title":"Lancet."},{"issue":"6","key":"718_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.smim.2009.08.003","volume":"21","author":"RL Zuvich","year":"2009","unstructured":"Zuvich RL, McCauley JL, Pericak-Vance MA, Haines JL. Genetics and pathogenesis of multiple sclerosis. Semin Immunol. 2009;21(6):328\u201333.","journal-title":"Semin Immunol."},{"issue":"24","key":"718_CR6","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1212\/WNL.0b013e3181e3973f","volume":"74","author":"H Tremlett","year":"2010","unstructured":"Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74(24):2004\u201315.","journal-title":"Neurology."},{"key":"718_CR7","unstructured":"European Medicines Agency (EMA). Tysabri: summary of product characteristics. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000603\/WC500044686.pdf . Accessed Aug 2017."},{"key":"718_CR8","unstructured":"European Medicines Agency (EMS). Gilenya: summary of product characteristics. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002202\/WC500104528.pdf . Accessed Aug 2017."},{"issue":"Pt 3","key":"718_CR9","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/brain\/awm329","volume":"131","author":"LK Fisniku","year":"2008","unstructured":"Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131(Pt 3):808\u201317.","journal-title":"Brain."},{"key":"718_CR10","unstructured":"National Institute for Health and Care Excellence (NICE). Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis [TA127]. 2007. https:\/\/www.nice.org.uk\/search?q=TA127 . Accessed Aug 2017."},{"key":"718_CR11","unstructured":"National Institute for Health and Care Excellence (NICE). Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis [TA254]. 2012. https:\/\/www.nice.org.uk\/guidance\/ta254 . Accessed Aug 2017."},{"key":"718_CR12","unstructured":"National Institute for Health and Care Excellence (NICE). Alemtuzumab for treating relapsing-remitting multiple sclerosis [TA312]. 2014. https:\/\/www.nice.org.uk\/search?q=TA312 . Accessed Aug 2017."},{"key":"718_CR13","unstructured":"National Institute for Health and Care Excellence (NICE). Daclizumab for treating relapsing-remitting multiple sclerosis [TA441]. 2017. https:\/\/www.nice.org.uk\/guidance\/ta441 . Accessed Aug 2017."},{"key":"718_CR14","unstructured":"European Medicines Agency (EMA). EMA review of Zinbryta confirms medicine\u2019s risks outweigh its benefits. 2018. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/Zinbryta\/human_referral_prac_000074.jsp&mid=WC0b01ac05805c516f . Accessed 2 May 2018."},{"issue":"1","key":"718_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","volume":"34","author":"TP Leist","year":"2011","unstructured":"Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34(1):28\u201335.","journal-title":"Clin Neuropharmacol."},{"key":"718_CR16","unstructured":"Merck. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis [ID64]: company evidence submission to NICE. 2017."},{"key":"718_CR17","unstructured":"European Medicines Agency (EMA). Mavenclad: summary of opinion (initial authorisation). 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/004230\/WC500229786.pdf . Accessed Aug 2017."},{"key":"718_CR18","volume-title":"Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis [ID64]: a single technology appraisal","author":"R Duarte","year":"2017","unstructured":"Duarte R, Mahon J, Nevitt S, Greenhalgh J, Boland A, Beale S, et al. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis [ID64]: a single technology appraisal. Liverpool: University of Liverpool, LRIG; 2017."},{"key":"718_CR19","unstructured":"Merck. CLARITY clinical trial report, Study 25643. 2010."},{"issue":"5","key":"718_CR20","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416\u201326.","journal-title":"N Engl J Med."},{"key":"718_CR21","unstructured":"Merck. CLARITY clinical study protocol, Study 25643. 2008."},{"key":"718_CR22","unstructured":"Merck. CLARITY GEVD subgroup analyses. 2017."},{"issue":"4","key":"718_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","volume":"10","author":"G Giovannoni","year":"2011","unstructured":"Giovannoni G, Cook S, Rammohan K, Rieckmann P, S\u00f8rensen PS, Vermersch P, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10(4):329\u201337.","journal-title":"Lancet Neurol."},{"key":"718_CR24","unstructured":"Merck. CLARITY EXT clinical trial report, Study 27820. 2016."},{"issue":"10","key":"718_CR25","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/sim.7224","volume":"36","author":"L Li","year":"2017","unstructured":"Li L, Tang S, Jiang L. On an enhanced rank-preserving structural failure time model to handle treatment switch, crossover, and dropout. Stat Med. 2017;36(10):1532\u201347.","journal-title":"Stat Med."},{"issue":"9139","key":"718_CR26","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","volume":"352","author":"GC Ebers","year":"1998","unstructured":"Ebers GC. Randomised double-blind placebo-controlled study of interferon \u03b2-1a in relapsing\/remitting multiple sclerosis. Lancet. 1998;352(9139):1498\u2013504.","journal-title":"Lancet."},{"key":"718_CR27","unstructured":"NICE Decision Support Unit. Technical support document 3 (TSD3): heterogeneity: subgroups, meta-regression, bias and bias-adjustment. 2011. http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/TSD3-Heterogeneity.final-report.08.05.12.pdf . Accessed Aug 2017."},{"issue":"1","key":"718_CR28","doi-asserted-by":"publisher","first-page":"e004073","DOI":"10.1136\/bmjopen-2013-004073","volume":"4","author":"J Palace","year":"2014","unstructured":"Palace J, Bregenzer T, Tremlett H, Oger J, Zhu F, Boggild M, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open. 2014;4(1):e004073.","journal-title":"BMJ Open."},{"issue":"5","key":"718_CR29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1474-4422(15)00018-6","volume":"14","author":"J Palace","year":"2015","unstructured":"Palace J, Duddy M, Bregenzer T, Lawton M, Zhu F, Boggild M, et al. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK multiple sclerosis risk sharing scheme at 6\u00a0years: a clinical cohort study with natural history comparator. Lancet Neurol. 2015;14(5):497\u2013505.","journal-title":"Lancet Neurol."},{"issue":"4","key":"718_CR30","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jval.2016.01.002","volume":"19","author":"A Hawton","year":"2016","unstructured":"Hawton A, Green C. Health utilities for multiple sclerosis. Value Health. 2016;19(4):460\u20138.","journal-title":"Value Health."},{"issue":"1","key":"718_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","volume":"10","author":"M Orme","year":"2007","unstructured":"Orme M, Kerrigan J, Tyas D, Russell N, Nixon R. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health. 2007;10(1):54\u201360.","journal-title":"Value Health."},{"key":"718_CR32","unstructured":"National Institute for Health and Care Excellence (NICE). Teriflunomide for treating relapsing-remitting multiple sclerosis [TA303]. 2014. https:\/\/www.nice.org.uk\/guidance\/ta303 . Accessed Aug 2017."},{"key":"718_CR33","unstructured":"National Institute for Health and Care Excellence (NICE). Dimethyl fumarate for treating relapsing-remitting multiple sclerosis [TA320]. 2014. https:\/\/www.nice.org.uk\/guidance\/ta320 . Accessed Aug 2017."},{"key":"718_CR34","unstructured":"National Institute for Health and Care Excellence (NICE). Beta interferon and glatiramer acetate for the treatment of multiple sclerosis [TA32]. 2002. https:\/\/www.nice.org.uk\/Guidance\/ta32 . Accessed Aug 2017."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-018-0718-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0718-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0718-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T11:57:44Z","timestamp":1720699064000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-018-0718-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,16]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["718"],"URL":"https:\/\/doi.org\/10.1007\/s40273-018-0718-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,16]]},"assertion":[{"value":"16 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This project was funded by the National Institute for Health Research Health Technology Programme (project no. 15\/194\/10; see the Health Technology Assessment programme website for further project information,). The views and opinions expressed are those of the authors and do not necessarily reflect those of the National Institute of Health and Care Excellence or the Department of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tosin Lambe, Rui Duarte, James Mahon, Sarah Nevitt, Janette Greenhalgh, Angela Boland, Sophie Beale, Eleanor Kotas, Joanne McEntee and Ian Pomeroy have no conflicts of interest that are directly relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}